Cooperative Agreement U01FD008279
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$350K
Funding Federal Agency
Center for Drug Evaluation and Research
Awarding Federal Agency
FDA Office of Acquisition and Grant Services
Federal Grant Program
93.103
Assistance Type
Cooperative Agreement
Place of Performance
Washington, DC, USA
Similar Awards
This $249,999.00 Cooperative Agreement awarded by the Center for Drug Evaluation and Research (CDER) of the U.S. Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) aims to mechanistically and systematically understand the effect of formulation composition, design, excipients, manufacturing methods, and process parameters on alcohol-induced dose dumping in extended-release drug products. The objectives are to investigate drug-related, formulation-related, and...
This $2,490,060 Cooperative Agreement award from the National Institutes of Health (NIH) Office of the Director under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077) supports research to optimize public health communication strategies on the continuum of risk for tobacco products. The project aims to assess the effects of FDA tobacco product risk continuum messaging on adult combustible tobacco users and youth/young adult tobacco users or...
This Cooperative Agreement award from the National Institute on Alcohol Abuse and Alcoholism (NIAAA), under the Alcohol Research Programs (CFDA 93.273), provides $999,393.00 to support Investigational New Drug (IND)-enabling studies for a novel therapeutic targeting the hypothalamic-pituitary-adrenal (HPA) axis for the treatment of Alcohol Use Disorder (AUD). The awardee, Stress Therapeutics, Inc., a for-profit company in San Diego, California, will manufacture and validate the test article,...
This $28,000,000 Cooperative Agreement awarded by the Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) supports the National Environmental Health Association (NEHA) in a multi-year project to expand state, local, tribal, and territorial (SLTT) conformance with the Voluntary National Retail Food Regulatory Program Standards. The key objectives of this project are to: 1) Develop and improve a grant management system to provide financial assistance to SLTT retail food...
The U.S. Food and Drug Administration (FDA) awarded a $249,485 Cooperative Agreement under the FDA Research program (CFDA 93.103) to Simulations Plus Inc. for the project "From Bench to Bioequivalence: In Vitro Mechanistic Understanding of ASD Drug Products in Simulated Gastrointestinal Conditions." The project aims to enhance understanding of how food and gastric pH affect the release of drugs from amorphous solid dispersions (ASDs) and how formulation and manufacturing variability...
This $499,774 cooperative agreement from the Department of Health and Human Services' Food and Drug Administration will support the University of California, San Diego in qualifying composite quantitative imaging biomarkers for diagnostic enrichment in nonalcoholic steatohepatitis (NASH) clinical trials. Over the one-year period from September 1, 2022 to August 31, 2023, UC San Diego will prepare and submit a biomarker qualification plan to the FDA's Center for Drug Evaluation and Research...
This Cooperative Agreement award from the Food and Drug Administration (FDA) Research program (CFDA 93.103) provides $249,826 in funding to The Critical Path Institute (C-Path) to complete psychometric analyses and develop a quantitative study report to support the qualification of the Chronic Heart Failure Symptom Scale (CHF-SS) as a fit-for-purpose clinical outcome assessment for regulatory decision-making in heart failure drug development. The project involves three main aims: 1) finalizing...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,536 to Chemregen Inc.'s Human Biomolecular Research Institute in San Diego, CA. The funding supports research to design, synthesize, and test non-opioid drug candidates as potential treatments for opioid use disorder and fentanyl toxicity. Key objectives include characterizing the effects of opioids on human induced pluripotent stem...
This Cooperative Agreement award from the U.S. Food and Drug Administration (FDA) under the FDA Research program (CFDA 93.103) provides $1,500,000 in funding to the World Health Organization (WHO) over a 60-month period from September 1, 2024 to August 31, 2029. The goal of this project is to strengthen regulatory systems to improve global food and medical product quality and safety. Key objectives include achieving oversight and building capacities for regulatory oversight in WHO member states,...
This Project Grant award of $622,957 from the National Institutes of Health (NIH) Office of the Director, under the Family Smoking Prevention and Tobacco Control Act Regulatory Research program (CFDA 93.077), supports research by Duke University to investigate the chemical composition and behavioral effects of novel tobacco products, including oral nicotine pouches and "non-menthol" cigarettes. The study aims to analyze the flavors, sweeteners, and nicotine forms in these products, and...